Bioengineering & Technology platform

Frontpage image: The Bioengineering and Technology platform is located within the AGORA translational cancer research center next to the CHUV hospital. Inserts show Lgr5-GFP organoids. Image copyrights: ISREC foundation

Gaspard Pardon

Located in the new AGORA Cancer Research Center next to the CHUV hospital in Lausanne, the platform aims to serve as a bidirectional bridge between the biomedical and EPFL research communities. We enable your translational research with bioengineering technologies and knowhow. We augment your technological research by facilitating access to the clinical and translational landscape and expertise.

Gaspard Pardon, Head of PTBET

The BET in short

Our vision and mission

The Bioengineering and Technology (BET) platform is a new platform of EPFL School of Life Sciences. The BET platform is currently being established at the AGORA Cancer Research Center in Lausanne.

The BET platform aims to serve as a bidirectional bridge between the biomedical and EPFL research communities. Our aim is to develop and share expertise in the space of translational bioengineering.

  • We enable your translational research with with the latest technologies and knowhow coming out of EPFL and the larger engineering community.
  • We augment and accelerate your engineering of innovative assays and technologies by facilitating access to the clinical and translational landscape and expertise.

While primarily focused on the needs of the cancer research community, the BET platform aims to enable innovation, support research and federate the wider interdisciplinary community active in translational bioengineering.

As a center of expertise in translational bioengineering, the platform encompasses educational activities, research and development, and an open-access facility infrastructure to support your research needs along three main axes: 

  • rapid micro-fabrication and prototyping of microfluidic and organ-on-chip systems.
  • organoids and advanced cellular models, culture and assay developments.
  • specialised instrumentation for the development and implementation of custom experimental assays, including high-throughput microfluidics, assay automation, and high-content imaging.

News & Highlights

 

 

 

  • We expect the infrastructure and team to be installed and grow during the summer and fall 2021, stay tuned!

 

Follow us